Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wegovy, Zepbound and Eli Lilly
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Wegovy and Zepbound are leading this year's weight loss drug prescription surge
The weight loss revolution is in full swing, with the number of patients receiving Wegovy (NVO) having doubled while those receiving Zepbound have tripled since January 2024.
Weight loss drugs: Zepbound vs Wegovy
It appears not all weight-loss drugs are created equal. The users of one drug report more weight loss comparted to another brand. Dr. Bill Hartman from UW Health joined FOX6 to chat about that and other health topics.
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
2d
on MSN
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
JD Supra
13h
Novo Nordisk Urges FDA to Ban Compounded Semaglutide – What Weight-Loss Clinic Owners Need to Know
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
STAT
10h
European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...
FiercePharma
16h
AbbVie’s Skyrizi retains DTC spending crown, as Novo’s Wegovy sees first entry
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
11h
Novo Holdings' $16.5 Billion Catalent Buy Wins EU Antitrust Approval
BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S.
2d
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Hosted on MSN
1d
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from ...
BioPharma Dive
2d
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
GlobalData on MSN
8d
Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...
FiercePharma
2d
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
2d
on MSN
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million
By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Eli Lilly and Company
Zepbound
Feedback